Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Barinthus Biotherapeutics (NASDAQ: BRNS) announced that updated clinical data from its chronic hepatitis B program will be presented at The Liver Meeting® 2024 in San Diego. The late-breaking presentation will focus on VTP-300 combined with low-dose nivolumab and its association with HBsAg loss in specific chronic hepatitis B patients. The company will also participate in several medical congresses including the International Workshop on HBV Cure 2024 and the BSI Immune Therapies Summit. Additionally, management will attend investor conferences including Guggenheim's Healthcare Innovation Conference and Jefferies London Healthcare Conference for presentations and one-to-one meetings.
Barinthus Biotherapeutics (NASDAQ: BRNS) ha annunciato che i dati clinici aggiornati del suo programma per l'epatite B cronica saranno presentati a The Liver Meeting® 2024 a San Diego. La presentazione dell'ultimo minuto si concentrerà su VTP-300 combinato con nivolumab a bassa dose e sulla sua associazione con la perdita di HBsAg in specifici pazienti affetti da epatite B cronica. L'azienda parteciperà anche a diversi congressi medici, tra cui l'International Workshop on HBV Cure 2024 e il BSI Immune Therapies Summit. Inoltre, la direzione parteciperà a conferenze per investitori, tra cui la Healthcare Innovation Conference di Guggenheim e la Jefferies London Healthcare Conference per presentazioni e incontri individuali.
Barinthus Biotherapeutics (NASDAQ: BRNS) anunció que los datos clínicos actualizados de su programa de hepatitis B crónica se presentarán en The Liver Meeting® 2024 en San Diego. La presentación de último minuto se centrará en VTP-300 combinado con nivolumab a baja dosis y su asociación con la pérdida de HBsAg en pacientes específicos con hepatitis B crónica. La empresa también participará en varios congresos médicos, incluyendo el Taller Internacional sobre la Cura de HBV 2024 y la Cumbre de Terapias Inmunológicas BSI. Además, la dirección asistirá a conferencias para inversores, incluyendo la Healthcare Innovation Conference de Guggenheim y la Jefferies London Healthcare Conference para presentaciones y reuniones uno a uno.
Barinthus Biotherapeutics (NASDAQ: BRNS)는 만성 간염 B 프로그램의 업데이트된 임상 데이터가 샌디에고에서 열리는 The Liver Meeting® 2024에서 발표될 것이라고 발표했습니다. 이번 마지막 순간 발표는 저용량 니볼루맙과 함께 사용된 VTP-300 및 특정 만성 간염 B 환자에서의 HBsAg 손실과의 연관성에 중점을 둘 것입니다. 회사는 또한 HBV 치료 국제 워크숍 2024 및 BSI 면역 치료 정상 회담을 포함한 여러 의학 회의에 참석할 것입니다. 또한 경영진은 Guggenheim의 의료 혁신 회의 및 Jefferies 런던 의료 회의와 같은 투자자 회의에 참석하여 발표 및 일대일 미팅을 진행할 예정입니다.
Barinthus Biotherapeutics (NASDAQ: BRNS) a annoncé que des données cliniques mises à jour de son programme sur l'hépatite B chronique seront présentées lors de The Liver Meeting® 2024 à San Diego. La présentation de dernière minute se concentrera sur VTP-300 associé à une faible dose de nivolumab et son association avec la perte de HBsAg chez des patients spécifiques atteints d'hépatite B chronique. L'entreprise participera également à plusieurs congrès médicaux, y compris l'Atelier International sur la Guérison de l'HBV 2024 et le Sommet sur les Thérapies Immunitaires BSI. De plus, la direction assistera à des conférences pour investisseurs, y compris la Healthcare Innovation Conference de Guggenheim et la Jefferies London Healthcare Conference pour des présentations et des réunions individuelles.
Barinthus Biotherapeutics (NASDAQ: BRNS) gab bekannt, dass aktualisierte klinische Daten aus seinem chronischen Hepatitis B-Programm auf The Liver Meeting® 2024 in San Diego präsentiert werden. Die kurzfristige Präsentation wird sich auf VTP-300 in Kombination mit niederdosiertem Nivolumab und dessen Verbindung zum HBsAg-Verlust bei spezifischen chronischen Hepatitis B-Patienten konzentrieren. Das Unternehmen wird auch an mehreren medizinischen Kongressen teilnehmen, darunter dem International Workshop on HBV Cure 2024 und dem BSI Immune Therapies Summit. Darüber hinaus wird das Management an Investorenkonferenzen teilnehmen, einschließlich der Healthcare Innovation Conference von Guggenheim und der Jefferies London Healthcare Conference, um Präsentationen und persönliche Gespräche zu führen.
- None.
- None.
Insights
The late-breaking presentation at AASLD 2024 regarding VTP-300's clinical data in chronic hepatitis B treatment warrants attention. The key focus is on the combination therapy of VTP-300 with low-dose nivolumab leading to HBsAg loss in specific patients with HBsAg levels below 200 IU/mL. This could represent a significant advancement in HBV treatment.
However, without specific efficacy data, safety profiles, or detailed trial results being presented in this announcement, it's premature to assess the actual clinical impact. The presentation's late-breaking status suggests potentially meaningful findings, but investors should wait for the actual data presentation at the conference before drawing conclusions about the therapy's commercial potential.
OXFORD, United Kingdom, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, today announced that updated clinical data from its chronic hepatitis B program will be highlighted as a late breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2024 being held November 15-19, 2024 in San Diego, California and attendance at multiple conferences in November:
Medical Congresses
AASLD – The Liver Meeting® 2024:
- Late breaking abstract accepted as oral presentation.
- Title: VTP-300 combined with low-dose nivolumab is associated with HBsAg loss in certain chronic hepatitis B participants with HBsAg less than 200 IU/mL: Results from a phase 2b open-label study.
International Workshop on HBV Cure 2024:
- Formal presentation titled “HBsAg Levels and T Cell Boost in Patients with HBsAg Decline”, on November 13, 2024 at 16:50 ET.
British Society for Immunology (BSI) Immune Therapies Summit:
- Formal presentation titled "SNAP-TI Nanoparticles Induce Antigen-Specific Tolerance", between November 25 and 26, 2024.
Investor Banking Conferences
Guggenheim's Inaugural Healthcare Innovation Conference:
- Fireside Chat with Bill Enright, Chief Executive Officer, on November 11, 2024 at 14:00 ET.
- Barinthus Bio’s management will be available for one-to-one meetings between November 11 and 15, 2024.
Jefferies London Healthcare Conference:
- Barinthus Bio’s management will be available for one-to-one meetings between November 19 and 21, 2024.
To access recordings and materials associated with the events, please visit: https://investors.barinthusbio.com/events-presentations.
About Barinthus Bio
Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around our proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in infectious diseases and autoimmunity, including: VTP-300, that utilizing our ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection and VTP-1000, utilizing our SNAP-Tolerance Immunotherapy (SNAP-TI) platform and is designed to treat people with celiac disease. Barinthus Bio is also conducting a Phase 1 clinical trial for VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Bio’s differentiated technology platforms and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with chronic infectious diseases and autoimmunity. For more information, visit www.barinthusbio.com.
Forward Looking Statements
This press release contains forward-looking statements regarding Barinthus Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “may,” “will,” “plan,” “forward,” “encouraging,” “believe,” “potential,” “expect,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements regarding our future expectations, plans and prospects, including our product development activities and clinical trials, including timing for readouts of any preliminary, interim or final data for any of our programs, our anticipated regulatory filings and approvals, our cash runway, and our ability to develop and advance our current and future product candidates and programs. Any forward-looking statements in this press release are based on our management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the success, cost and timing of our pipeline development activities and planned and ongoing clinical trials, including the risk that the timing for preliminary, interim or final data or initiation of our clinical trials may be delayed, the risk that interim or topline data may not reflect final data or results, our ability to execute on our strategy, regulatory developments, the risk that we may not achieve the anticipated benefits of our pipeline prioritization and corporate restructuring, our ability to fund our operations and access capital, our cash runway, including the risk that our estimate of our cash runway may be incorrect, global economic uncertainty, including disruptions in the banking industry, the conflicts in Ukraine, Israel and Gaza, and other risks identified in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We expressly disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
IR contacts:
Christopher M. Calabrese
Managing Director
LifeSci Advisors
+1 917-680-5608
ccalabrese@lifesciadvisors.com
Kevin Gardner
Managing Director
LifeSci Advisors
+1 617-283-2856
kgardner@lifesciadvisors.com
Media contact:
Audra Friis
Sam Brown, Inc.
+1 917-519-9577
audrafriis@sambrown.com
Company contact:
Jonothan Blackbourn
IR & PR Manager
Barinthus Bio
ir@barinthusbio.com
FAQ
When will Barinthus Bio (BRNS) present at AASLD The Liver Meeting 2024?
What is the focus of Barinthus Bio's (BRNS) late-breaking presentation at AASLD 2024?
Which investor conferences will Barinthus Bio (BRNS) attend in November 2024?
